MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peng, S.
Right arrow Articles by Atchison, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peng, S.
Right arrow Articles by Atchison, W. D.

Vol. 62, Issue 6, 1418-1430, December 2002

Characteristics of Block by Pb2+ of Function of Human Neuronal L-, N-, and R-Type Ca2+ Channels Transiently Expressed in Human Embryonic Kidney 293 Cells

Shuangqing Peng, Ravindra K. Hajela, and William D. Atchison

Department of Pharmacology and Toxicology, Institute of Environmental Toxicology and Neuroscience Program, Michigan State University, East Lansing, Michigan

Lead (Pb2+) is a well-known inhibitor of voltage-dependent Ca2+ channels in their native environments in several types of cells. However, its effects on discrete Ca2+ channel phenotypes in isolation have not been well studied. We compared how specific subtypes of human neuronal high-voltage-activated Ca2+ channels were affected by acute exposure to Pb2+. Expression cDNA clones of human alpha 1C, alpha 1B, or alpha 1E subunit genes encoding neuronal L-, N-, and R-subtypes of Ca2+ channels, respectively, along with a constant alpha 2delta and beta 3 subunits were transfected into human embryonic kidney 293 cells. Currents through the respective transiently expressed channels were measured using whole-cell recording techniques with Ba2+ (20 mM) as charge carrier. Extracellular bath applications of Pb2+ significantly reduced current amplitude through all three types of Ca2+ channels in a concentration-dependent manner. The order of potency was: alpha 1E (IC50 = 0.10 µM), followed by alpha 1C (IC50 = 0.38 µM) and alpha 1B (IC50 = 1.31 µM). Pb2+-induced perturbation of function of alpha 1C and alpha 1B containing Ca2+ channels was more easily reversed than for alpha 1E-containing Ca2+ channels after washing with Pb2+ free solution. The current-voltage relationships were not altered after 3-min exposure to Pb2+ for any of the three types. However, the steady-state inactivation relationships were shifted to more negative potentials for channels containing alpha 1B and alpha 1E subunits, but not for those containing alpha 1C subunits. Pb2+ accelerated the inactivation time of current in all three subtypes of Ca2+ channels in a concentration- and voltage-dependent manner. Therefore, different subtypes of Ca2+ channels exhibit differential susceptibility to Pb2+ even when expressed in the same cell type. Current expressed by alpha 1E-containing channels is more sensitive to Pb2+ than that expressed by alpha 1C- or alpha 1B-containing channels. Several Ca2+ channel phenotypes are quite sensitive to the inhibitory action of Pb2+. Furthermore, it seems that Pb2+ is more likely to combine with Ca2+ channels in the closed state.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
H.-W. Kang, J.-Y. Park, S.-W. Jeong, J.-A. Kim, H.-J. Moon, E. Perez-Reyes, and J.-H. Lee
A Molecular Determinant of Nickel Inhibition in Cav3.2 T-type Calcium Channels
J. Biol. Chem., February 24, 2006; 281(8): 4823 - 4830.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics